These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 11758611)

  • 1. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein.
    Iacovazzi PA; Trisolini A; Barletta D; Elba S; Manghisi OG; Correale M
    Clin Chem Lab Med; 2001 Oct; 39(10):961-5. PubMed ID: 11758611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis.
    Correale M; Giannuzzi V; Iacovazzi PA; Valenza MA; Lanzillotta S; Abbate I; Quaranta M; Caruso ML; Elba S; Manghisi OG
    Anticancer Res; 1999; 19(4C):3469-72. PubMed ID: 10629637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum protein 90K/Mac-2BP is an independent predictor of disease severity during hepatitis C virus infection.
    Kittl EM; Hofmann J; Hartmann G; Sebesta C; Beer F; Bauer K; Huber KR
    Clin Chem Lab Med; 2000 Mar; 38(3):205-8. PubMed ID: 10905755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
    Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
    PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are 90K/MAC-2BP serum levels correlated with poor prognosis in HCC patients? Preliminary results.
    Iacovazzi PA; Guerra V; Elba S; Sportelli F; Manghisi OG; Correale M
    Int J Biol Markers; 2003; 18(3):222-6. PubMed ID: 14535594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
    Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
    J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
    Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
    Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity of alpha fetoprotein for diagnosis of hepatocellular carcinoma in cirrhosis.
    Sarwar S; Khan AA; Tarique S
    J Coll Physicians Surg Pak; 2014 Jan; 24(1):18-22. PubMed ID: 24411536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.
    Soresi M; Magliarisi C; Campagna P; Leto G; Bonfissuto G; Riili A; Carroccio A; Sesti R; Tripi S; Montalto G
    Anticancer Res; 2003; 23(2C):1747-53. PubMed ID: 12820452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
    Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
    Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma.
    Mukozu T; Nagai H; Matsui D; Kanekawa T; Sumino Y
    Anticancer Res; 2013 Mar; 33(3):1013-21. PubMed ID: 23482775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein.
    Paul SB; Gulati MS; Sreenivas V; Madan K; Gupta AK; Mukhopadhyay S; Acharya SK
    Oncology; 2007; 72 Suppl 1():117-23. PubMed ID: 18087192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study.
    Shen Q; Fan J; Yang XR; Tan Y; Zhao W; Xu Y; Wang N; Niu Y; Wu Z; Zhou J; Qiu SJ; Shi YH; Yu B; Tang N; Chu W; Wang M; Wu J; Zhang Z; Yang S; Gu J; Wang H; Qin W
    Lancet Oncol; 2012 Aug; 13(8):817-26. PubMed ID: 22738799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
    Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
    Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma.
    Beneduce L; Castaldi F; Marino M; Quarta S; Ruvoletto M; Benvegnù L; Calabrese F; Gatta A; Pontisso P; Fassina G
    Cancer; 2005 Jun; 103(12):2558-65. PubMed ID: 15887222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
    Zekri AR; Youssef AS; Bakr YM; Gabr RM; Ahmed OS; Elberry MH; Mayla AM; Abouelhoda M; Bahnassy AA
    World J Gastroenterol; 2016 Apr; 22(16):4168-82. PubMed ID: 27122667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
    Jia X; Gao Y; Zhai D; Liu J; Cai J; Wang Y; Jing L; Du Z
    Technol Cancer Res Treat; 2016 Dec; 15(6):780-786. PubMed ID: 26370140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma.
    Yagmur E; Rizk M; Stanzel S; Hellerbrand C; Lammert F; Trautwein C; Wasmuth HE; Gressner AM
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):755-61. PubMed ID: 17700260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
    Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
    Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.